Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 24;22(1):570.
doi: 10.1186/s12879-022-07536-7.

Low positivity rates for HBeAg and HBV DNA in rheumatoid arthritis patients: a case-control study

Affiliations

Low positivity rates for HBeAg and HBV DNA in rheumatoid arthritis patients: a case-control study

Yue Jia et al. BMC Infect Dis. .

Abstract

Background: The rates of hepatitis B virus (HBV) infection in rheumatoid arthritis (RA) patients are controversial when considering the reported outcomes. It was speculated that HBV infection status was altered after RA, and variations inn HBV infection rates became apparent.

Methods: To compare the positive proportions of hepatitis B e antigen (HBeAg) and HBV DNA, a retrospective case-control study was performed between 27 chronic hepatitis B (CHB) patients with RA and 108 age- and gender-matched CHB patients. In addition, the positivity rates of hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) were surveyed among the 892 RA patients.

Results: Compared to CHB patients, CHB patients with RA exhibited lower rates of HBeAg positivity (11.1% vs. 35.2%, P = 0.003), HBV DNA positivity (37.0% vs. 63.9%, P = 0.007) and ALT elevation (11.1% vs. 35.2%, P = 0.024). In the 892 RA patients, the prevalence of HBsAg (3.0%) was lower than that reported in the Chinese national data (7.2%), whereas the anti-HBc positivity rate of 44.6% was higher than that of 34.1%.

Conclusion: HBV infection status was altered after suffering from RA. Compared to the matched CHB patients, low positive proportions of HBeAg and HBV DNA were observed for CHB patients with RA.

Keywords: Chronic hepatitis B; HBV; HBV DNA; HBeAg; Rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

All the authors declare that they have no competing interests, and all authors confirm its accuracy.

Figures

Fig. 1
Fig. 1
The comparison of HBV infection status between the RA patients and the age- and sex-matched CHB patients: A The comparison of HBeAg(+) rates; B The comparison of HBeAg titers; C The comparison of different HBV DNA gradients rates; D The comparison of HBV DNA load; E The comparison of elevated ALT rates; F The comparison of ALT levels. ALT alanine transaminase; CHB chronic Hepatitis B; HBeAg hepatitis B e antigen; HBsAg hepatitis B surface antigen; HBV hepatitis B virus; RA rheumatoid arthritis
Fig. 2
Fig. 2
The comparison of HBsAg(+) rate and anti-HBc(+) rates between the RA patients and the Chinese general population: A The comparison of HBsAg(+) rates; B The comparison of anti-HBc(+) rates. *The CGP data: CGP in 2006 [8], CGP in 2016 [14] and CGP from 2013 to 2017 [15]. anti-HBc hepatitis B core antibody; CGP Chinese general population; HBsAg hepatitis B surface antigen; RA rheumatoid arthritis

Similar articles

Cited by

References

    1. Olivieri I, Palazzi C, Padula A. Hepatitis C virus and arthritis. Rheum Dis Clin North Am. 2003;29(1):111–122. doi: 10.1016/S0889-857X(02)00097-2. - DOI - PubMed
    1. Sargin G, Kandemir A. Clinical utility of anti-cyclic citrullinated peptid and rheumatoid factor in chronic hepatitis B virus infection. Indian J Rheumatol. 2018;13(4):229–232. doi: 10.4103/injr.injr_82_18. - DOI
    1. Chen YL, Jing J, Mo YQ, Ma JD, Yang LJ, Chen LF, Zhang X, Yan T, Zheng DH, Pessler F, et al. Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis. Arthritis Res Ther. 2018;20(1):130. doi: 10.1186/s13075-018-1623-y. - DOI - PMC - PubMed
    1. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013;52(1):53–61. doi: 10.1093/rheumatology/kes305. - DOI - PubMed
    1. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, Ghogomu ET, Coyle D, Clifford T, Tugwell P, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258–265. doi: 10.1016/S0140-6736(14)61704-9. - DOI - PMC - PubMed